

## **Patent Updates**

## Suven Life Sciences secures Product Patents in ARIPO, Brazil and USA

HYDERABAD, INDIA (May 15, 2023) — Suven Life Sciences Ltd secures one (1) product patent from ARIPO (AP6702), three (3) product patents from Brazil (BR 11 2016 0107888-8, BRR 11 2017 002921-9 and BR 11 2017 026272-0) and one (1) product patent from USA (11622967) corresponding to the new Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2038, 2034, 2034, 2036 and 2038 respectively.

The granted claims of the patents include the class of selective H3, 5HT6 and M1PAM compounds and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia etc.

## **Disclaimer and Risk Statement:**

Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time.